Abstract 170P
Background
The KRAS gene plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). This study aimed to investigate the frequency of KRAS mutations in patients with PDAC.
Methods
From 2020 to 2023, we retrospectively analyzed the KRAS status in 45 patients with PDAC. The distribution of clinical stages and the frequency of other mutations such as NRAS and BRCA2 were also evaluated.
Results
Among 45 patients, 30 (66.7%) had KRAS mutations, with the most frequent being G12D (50%), followed by G12V (26.6%). Q61K, G12A, A146T, G12R, and G12C mutations were less common. One patient with G12V mutation also had a BRCA2 mutation. In the mutated KRAS (mKRAS) group, 13 patients (43.3%) had metastatic disease, 12 (40%) had localized disease, and 5 (16.6%) had locally advanced disease. In the wild-type KRAS (wtKRAS) group, which consisted of 15 patients (33.3%), 7 (46.7%) had metastatic disease, 5 (33.3%) had localized disease, and 3 (20%) had locally advanced disease. One patient with wtKRAS also had a germline BRCA2 mutation. The distribution of clinical stages did not differ significantly between mKRAS and wtKRAS groups. NRAS mutation analysis was conducted in 41 patients, and no mutations were detected.
Conclusions
Our study revealed a high frequency of wtKRAS in patients with PDAC. Further investigation is needed to expound the clinical significance of KRAS status in this patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract